Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors

Ecaterina E Dumbrava, Do-Youn Oh, Min-Hee Ryu, Emiliano Calvo, Elena Garralda, Wei-Pang Chung, Li-Yuan Bai, Katerin Rojas, Ozlem Yildirim, Serena Masciari, Gu Mi, Lei Wang, Federico Rotolo, Sarah Gailhac, Elham Attieh, Pinar Kanlikilicer, Barbara Buday, Raymond Perez, Faiza Rharbaoui, Giovanni Abbadessa, Victor Moreno

Open source

DOI: 10.1136/jitc-2025-014309
Published: 2026-09
Container: Journal for ImmunoTherapy of Cancer
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2025-014309,
  title = {Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors},
  author = {Ecaterina E Dumbrava and Do-Youn Oh and Min-Hee Ryu and Emiliano Calvo and Elena Garralda and Wei-Pang Chung and Li-Yuan Bai and Katerin Rojas and Ozlem Yildirim and Serena Masciari and Gu Mi and Lei Wang and Federico Rotolo and Sarah Gailhac and Elham Attieh and Pinar Kanlikilicer and Barbara Buday and Raymond Perez and Faiza Rharbaoui and Giovanni Abbadessa and Victor Moreno},
  year = {2026},
  journal = {Journal for ImmunoTherapy of Cancer},
  doi = {10.1136/jitc-2025-014309},
  url = {https://doi.org/10.1136/jitc-2025-014309}
}

RIS

TY  - JOUR
TI  - Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors
AU  - Ecaterina E Dumbrava
AU  - Do-Youn Oh
AU  - Min-Hee Ryu
AU  - Emiliano Calvo
AU  - Elena Garralda
AU  - Wei-Pang Chung
AU  - Li-Yuan Bai
AU  - Katerin Rojas
AU  - Ozlem Yildirim
AU  - Serena Masciari
AU  - Gu Mi
AU  - Lei Wang
AU  - Federico Rotolo
AU  - Sarah Gailhac
AU  - Elham Attieh
AU  - Pinar Kanlikilicer
AU  - Barbara Buday
AU  - Raymond Perez
AU  - Faiza Rharbaoui
AU  - Giovanni Abbadessa
AU  - Victor Moreno
PY  - 2026
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2025-014309
UR  - https://doi.org/10.1136/jitc-2025-014309
ER  -

APA

Dumbrava, E. E., Oh, D., Ryu, M., Calvo, E., Garralda, E., Chung, W., Bai, L., Rojas, K., Yildirim, O., Masciari, S., Mi, G., Wang, L., Rotolo, F., Gailhac, S., Attieh, E., Kanlikilicer, P., Buday, B., Perez, R., Rharbaoui, F., Abbadessa, G., & Moreno, V. (2026). Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014309

Source records

crossref · retrieved 2026-09-25T19:02:14.087Z